Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 15/20 | 0.60 |
| ▸ | SOAT1 | P35610 | 10/20 | 0.58 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | KMO | O15229 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2254137 | 0.86 | DGAT1 (0.68) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL5532585 | 0.86 | DGAT1 (0.72) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL23339907 | 0.83 | DGAT1 (0.67) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL5532388 | 0.81 | DGAT1 (0.77) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL5538522 | 0.80 | DGAT1 (0.63) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL2126247 | 0.76 | DGAT1 (0.65) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL5532372 | 0.75 | DGAT1 (1.00) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL16500237 | 0.75 | DGAT1 (0.64) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL18397596 | 0.74 | KMO (0.69) | DHODHKMO | |
| SCHEMBL14683877 | 0.73 | KMO (0.87) | DHODHKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234978-B1 | CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 | ASTRAZENECA AB (SE) | 2015-02-25 | — | — | EP | disclosed |
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-7994179-B2 | Carbamoyl compounds as DGAT1 inhibitors 190 | ASTRAZENECA AB (SE) | 2011-08-09 | — | — | US | disclosed |
| US-7994179-B2 | Carbamoyl compounds as DGAT1 inhibitors 190 | ASTRAZENECA AB (SE) | 2011-08-09 | — | — | US | disclosed |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| WO-2009081195-A1 | CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885SOAT1 3/4885DHODH 567/4885 |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885SOAT1 3/4885DHODH 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.